Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

US pharma giant Merck & Co (NYSE: MRK) today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met ...

Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.

Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer. Immutep climbed 16% to $2.11 on ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...